In vitro susceptibility of nonfermenting Gram-negative rods to meropenem–vaborbactam and delafloxacin - Université de Reims Champagne-Ardenne
Article Dans Une Revue Future Microbiology Année : 2023

In vitro susceptibility of nonfermenting Gram-negative rods to meropenem–vaborbactam and delafloxacin

Résumé

Aim: Meropenem–vaborbactam and delafloxacin activities were not assessed against Achromobacter spp. ( Achr), Burkholderia cepacia complex ( Bcc) and Stenotrophomonas maltophilia ( Smal). Methodology: A total of 106 Achr, 57 Bcc and 100 Smal were tested with gradient diffusion test of meropenem–vaborbactam, delafloxacin and comparators. Results: Meropenem–vaborbactam MIC 50 were 4 μg/ml for Achr, 1 μg/ml for B. cepacia, 2 μg/ml for B. cenocepacia and B. multivorans, and 32 μg/ml for Smal. Delafloxacin MIC 50 were 4 μg/ml for Achr, 0.25 μg/ml for B. cepacia and B. multivorans, 2 μg/ml for B. cenocepacia, and 0.5 μg/m for Smal. meropenem–vaborbactam MICs were fourfold lower than meropenem for 28.3% Achr, 77.2% B. cepacia, 53.8% B. cenocepacia and 77.2% B. multivorans. Conclusion: Meropenem–vaborbactam and delafloxacin are in vitro active against Bcc and Achr.
Fichier non déposé

Dates et versions

hal-03978223 , version 1 (08-02-2023)

Identifiants

Citer

Eric Farfour, Louise Ruffier D’epenoux, Anaëlle Muggeo, Sylvie de Verdière, Corentine Alauzet, et al.. In vitro susceptibility of nonfermenting Gram-negative rods to meropenem–vaborbactam and delafloxacin. Future Microbiology, 2023, ⟨10.2217/fmb-2021-0278⟩. ⟨hal-03978223⟩
34 Consultations
0 Téléchargements

Altmetric

Partager

More